A litigation funding agreement is the contract that governs how a third-party funder finances legal claims in exchange for a share of the proceeds if the case succeeds. For investors, it sits within the broader universe of non-correlated strategies discussed in our guide to alternative vs traditional investing, but it has a very different risk profile to property, private credit, or equities: outcomes are driven by legal merits, procedure, and timing rather than market cycles.
This article focuses on the mechanics investors should understand before allocating capital: how returns are calculated, what control (if any) a funder has, how long money can be tied up, and where the downside risk actually sits.
What a litigation funding agreement is (and what it is not)
At its core, a litigation funding agreement is a funding contract between:
- The funded party (usually a claimant, sometimes a law firm in certain structures),
- The funder (an investor or specialist funding firm), and
- Often, the lawyers (via side letters or acknowledgements covering payment mechanics, confidentiality, and cooperation).
The funder pays some or all of the costs of pursuing a claim (legal fees, expert reports, court fees, insurance premiums, and sometimes working capital). If the claim loses, the funder typically does not get repaid (non-recourse), subject to exceptions spelled out in the agreement (for example, fraud, misrepresentation, or material breach).
What it is not: a typical litigation funding agreement is not a secured loan, not a guaranteed return product, and not an investment where the investor can freely trade out at any time. The enforceability of terms can also depend on the jurisdiction, including rules around maintenance/champerty and how courts view funder involvement.
How the structure works in practice
1) Capital commitment and drawdowns
Many arrangements are budget-based. The funder agrees to finance an approved budget (or a capped amount) and the claimant’s lawyers draw funds as costs are incurred. Key drafting points include:
- Funding limit (maximum capital exposure),
- Approved budget (what is covered and what requires consent),
- Drawdown process (invoice review, timing, and dispute mechanism), and
- Cost overruns (who pays if the case becomes more expensive than expected).
2) Use of proceeds
Agreements often restrict how capital can be used (e.g., only for litigation expenses related to the claim) and can require periodic reporting on spend versus budget. If the funded party wants the funder to cover additional claims, appeals, or enforcement actions, that usually requires an amendment or a new funding tranche.
3) Case outcomes and the “waterfall”
When the case resolves (judgment, settlement, or arbitration award), proceeds typically flow through a defined priority of payments (the waterfall). While each deal differs, the typical sequence is:
Recoveries 9 taxes/court deductions 9 adverse-costs/insurance obligations (if any) 9 legal fees and disbursements 9 repayment of funded amounts 9 funder’s return 9 claimant’s net proceeds.
The precise order matters because it determines whether the investor’s return is effectively senior to other payments or diluted by them. It also determines the minimum settlement amount the claimant may accept while still satisfying the funder’s entitlement.
Return structures investors will see (and how they behave)
The economics in a litigation funding agreement are typically expressed in one (or a combination) of these forms:
- Multiple on invested capital (e.g., 2.0x of funded amounts),
- Percentage of proceeds (e.g., 25% of recoveries),
- IRR-based return (a compounding annual rate), or
- Hybrid (often “the greater of” a multiple or an IRR, sometimes capped).
Worked example: multiple vs IRR
Assume a funder advances $2,000,000 over time. The agreement entitles the funder to the greater of (a) 2.0x funded capital or (b) a 30% IRR, paid from proceeds after specified costs.
- If the case settles in 12 months, 30% IRR on $2,000,000 is roughly $2,600,000 (depending on drawdown timing). The 2.0x multiple would be $4,000,000, so the multiple could dominate.
- If the case resolves in 48 months, the IRR number can rise significantly and may exceed the 2.0x multiple, depending on the compounding and draw schedule.
This is why duration is a central driver of investor outcomes: time-to-resolution can move a deal from attractive to mediocre (or vice versa) even if the headline recovery is the same.
Fees, costs, and “return on costs” definitions
Investor-friendly drafting defines clearly what counts as “funded amounts” and what does not. Common points of friction include:
- Whether the funder’s return applies only to amounts actually drawn or also to committed but undrawn capital,
- Whether insurance premiums (like ATE cover) are included in funded amounts,
- How recoverable costs awarded by a court are treated (do they reduce funded amounts or increase recoveries?), and
- Whether interest on a judgment/award is included in “proceeds.”
Case control: who decides strategy and settlement?
Investors are often surprised by how carefully control is drafted. In many jurisdictions, funders cannot (and should not) run the case, but they will negotiate information rights and consent thresholds to protect capital. The goal is alignment without undermining privilege, independence of counsel, or enforceability.
Typical funder rights
- Information and reporting: budgets, pleadings, expert updates, key correspondence, and periodic status calls.
- Consent rights: approving material changes (e.g., adding defendants, changing counsel, major budget increases, moving to appeal).
- Settlement consultation: the claimant may retain formal settlement authority, but the funder often receives consultation rights and sometimes a mechanism to address disagreement.
Settlement disagreement mechanisms
A well-drafted litigation funding agreement includes a practical way to handle settlement disputes, such as:
- Independent counsel opinion on whether a proposed settlement is reasonable,
- Mediation between claimant and funder, and/or
- A pre-agreed “accept/reject” framework tied to expected value and downside risk.
This is critical because the claimant might prefer an early, lower settlement (to stop stress or reputational risk) while the funder prefers to continue for a higher expected payoff—or the reverse if downside risk grows.
Duration and liquidity: why timelines are hard to model
Litigation is not a standard cash-flow instrument. Even when a claim is strong on the merits, timelines can stretch due to procedural steps, court calendars, appeals, and enforcement. A realistic timeline analysis usually includes:
- Pre-action and pleadings (weeks to months),
- Disclosure/discovery (months),
- Expert evidence (months),
- Trial/arbitration hearing, and
- Appeals and enforcement (potentially years).
Because your capital may be tied up longer than planned, the decision to invest should fit your broader risk tolerance in investing, including your ability to withstand illiquidity and outcome uncertainty.
Downside risk: what “non-recourse” really means
Non-recourse means the funder’s primary remedy is limited to case proceeds: if there is no recovery, the funder typically loses its invested capital. However, the true downside depends on several contract and procedural factors.
Adverse costs and security for costs
In “loser pays” jurisdictions, a losing claimant may be ordered to pay the other side’s costs. Agreements may address adverse costs through:
- After-the-event (ATE) insurance,
- Adverse-cost reserves funded as part of the budget, or
- Contractual allocation of who bears these risks and when.
Courts may also order a claimant to provide security for costs (a deposit or guarantee). A funder may have to provide security directly or fund the claimant to do so, which can materially increase the capital required and extend duration.
Termination, breach, and clawback
Read the termination clause carefully. Common triggers include:
- Material adverse change in merits or recoverability,
- Fraud or misrepresentation by the funded party,
- Failure to cooperate with counsel, or
- Loss of privilege/confidentiality due to unauthorised disclosure.
Some agreements allow the funder to stop funding after a trigger while retaining an entitlement to a return from future proceeds. Investors should test whether that creates enforceability risk or misaligned incentives.
Recoverability and enforcement risk
Winning on paper is not the same as collecting cash. Enforcement risk is often underweighted. The agreement should address whether funding covers enforcement steps (asset tracing, freezing orders, recognition in other jurisdictions) and how proceeds are treated if recovery is staggered over time.
Key legal and regulatory considerations (jurisdiction matters)
The same commercial terms can be interpreted differently across legal systems. In the UK, recent developments have highlighted how contract classification can affect enforceability and regulation. Investors looking at UK-related claims should be aware of the UK Supreme Court’s PACCAR decision, which has influenced how certain funding arrangements may be treated under statutory frameworks.
Separately, some jurisdictions have adopted specific legislative frameworks for third-party funding. For example, Singapore has implemented rules for third-party funding in certain proceedings; see the Singapore Ministry of Law’s overview of the third-party funding framework for an official perspective.
Because the enforceability and disclosure requirements can vary, investors should ensure counsel reviews the agreement in the relevant seat/jurisdiction rather than relying on a generic template.
Investor checklist: clauses to scrutinise in a litigation funding agreement
Before committing capital, investors typically pressure-test these provisions:
- Definition of proceeds: does it include interest, costs recovered, and non-cash consideration?
- Priority of payments: where exactly does the funder sit in the waterfall?
- Budget governance: approval process, overruns, and scope changes.
- Settlement mechanics: consent rights, consultation obligations, and dispute resolution.
- Control boundaries: preserving lawyer independence and privilege while securing reporting.
- Adverse costs: insurance/reserves, who pays, and what happens if coverage is denied.
- Termination and consequences: when funding can stop and how returns are calculated post-termination.
- Duration and extension: what happens on appeal or enforcement, and whether additional funding is optional or mandatory.
- Confidentiality and privilege: information-sharing protocols and NDAs with experts/third parties.
- Assignment and syndication: whether the funder can sell/transfer its interest and under what conditions.
How investors evaluate expected value (without oversimplifying)
Investor underwriting often reduces a case to three pillars: (1) probability of success on the merits, (2) quantum (how much could be recovered), and (3) collectability (can it be enforced). But the agreement itself can amplify or reduce risk through:
- Return convexity (how much you gain in an upside vs what you lose in a downside),
- Time sensitivity (IRR exposure to delays), and
- Tail risk (adverse costs, security for costs, counterclaims, sanctions).
Practically, sophisticated investors run scenario analyses with different durations and settlement points, then compare the expected-value distribution against other private-market options and the portfolio’s liquidity needs.
FAQs
Is a litigation funding agreement the same as buying the claim?
Not usually. In many cases, the claimant remains the party to the litigation while the funder has a contractual right to a portion of proceeds. Some jurisdictions allow assignment or purchase of claims in limited circumstances, but this is highly context-dependent and often restricted.
Can a funder force a claimant to settle?
Often the claimant retains formal settlement authority, but the agreement may include consent thresholds, consultation requirements, or independent opinion processes. The practical influence of the funder depends on these clauses and the claimant’s ability to continue without funding.
What happens if the case takes longer than expected?
Delays can reduce the investor’s realised IRR and may require additional capital for extended legal work, appeals, or enforcement. Agreements should be explicit about whether further funding is optional, pre-approved within a cap, or subject to renegotiation.
What is the investor’s maximum loss?
In a typical non-recourse structure, the investor can lose the funded capital. However, additional exposures can arise indirectly (for example, through security for costs obligations or additional capital needed to protect the position), depending on how the agreement allocates these items.
Where this fits within alternative investing
Litigation funding can diversify a portfolio because its return drivers are largely legal and idiosyncratic. But it is not a passive, mark-to-market product: outcomes can be binary, timelines uncertain, and documentation critical. If you are exploring this area as part of a broader allocation, our alternative investments advisory service can help you assess suitability, structure risk, and ensure the opportunity fits your overall plan.
